Fulcrum Therapeutics Announces Departure of Chief Medical Officer
July 11, 2022 17:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)
July 05, 2022 07:00 ET
|
Fulcrum Therapeutics, Inc.
– REACH is the first Phase 3 trial for this rare, progressive, and debilitating muscular disease –– Losmapimod is an oral small molecule that has the potential to be the first therapy to treat...
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2022 16:02 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial
June 10, 2022 07:02 ET
|
Fulcrum Therapeutics, Inc.
- Achieved up to 6.3% hemoglobin F (HbF) induction in initial subjects in first cohort; HbF was increasing at last measured timepoint - Supports proof-of-concept that FTX-6058 is a novel oral HbF...
Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria
May 12, 2022 17:08 ET
|
Fulcrum Therapeutics, Inc.
- FTX-6058 is the only oral hemoglobin F (HbF) inducer in clinical development -Data will include initial HbF changes, safety, tolerability, pharmacokinetics, and other pharmacodynamic measures from...
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
May 09, 2022 07:00 ET
|
Fulcrum Therapeutics, Inc.
– Initial data from Phase 1b trial of FTX-6058 in sickle cell disease to be presented at the EHA 2022 Congress – – Phase 3 REACH trial of losmapimod in FSHD expected to begin in 2Q 2022 – –...
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 06, 2022 08:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference
May 05, 2022 08:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics to Host First Quarter 2022 Financial Results Conference Call and Webcast on Monday, May 9, 2022 at 8:00 a.m. ET
May 02, 2022 08:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 08, 2022 08:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...